55 Language as a Barrier to Deep Inspiration Breath Hold (DIBH) Radiation Therapy for Left Breast Cancer
Investigators Discontinue Vibostolimab Combo in Resected Melanoma Trial
The phase 3 KeyVibe-010 trial is unlikely to meet its primary end point of recurrence-free survival due to a high rate of treatment discontinuation.
Complementary and Alternative Medicine in Cancer Care: Does It Have a Role?
While treatment centered around multiple drug options is common practice in oncology, the use of complementary and medicine alternative medicine is being introduced in the space.
56 Predictive Factors Correlating With Pathologic Complete Response Rates in Racially Diverse, Minority Populations Receiving Neoadjuvant Therapy for HR+/HER2– Breast Cancer
Nivolumab ± Ipilimumab Yields Durable Responses in Cervical Cancer
The CheckMate 358 trial assessed various doses of nivolumab with or without ipilimumab for recurrent or metastatic cervical cancer.
57 Addressing Barriers to Identifying Patients With HER2-Low Metastatic Breast Cancer in a Large Community Oncology Practice
Nivolumab Combo Does Not Meet PFS End Point in Unresectable NSCLC
The progression-free survival end point was not met in the CheckMate -73L trial assessing patients with unresectable stage III non–small cell lung cancer.
Leveraging Surgical Oncology Advances in Colorectal Cancer Care
Gregory Charak, MD, discusses how modalities like laparoscopic surgery and neoadjuvant immunotherapy may benefit patients with colorectal cancer.
Lifileucel Yields Responses in Metastatic Non–Small Cell Lung Cancer
Phase 2 data support additional investigation of lifileucel as a treatment for patients with metastatic non–small cell lung cancer.
58 Prospective Longitudinal Assessment of Financial Toxicity Among Breast Cancer Patients
Nivolumab Meets ORR/PFS24 End Points in dMMR Uterine and Ovarian Cancer
Although the sample size for this trial was small, data still highlight a potential benefit with nivolumab in dMMR uterine and ovarian cancers.
59 Acceptability of Microbiome Sampling-Based Surgical Oncology Research in Minority Breast Cancer Patients
Nivolumab Combo Shows Efficacy, Safety in Muscle-Invasive Bladder Cancer
Phase 2 data support the potential of replacing cisplatin with nab-paclitaxel as a backbone therapy for those with muscle-invasive bladder cancer.
60 Racial Disparities in Hospitalization Outcomes Among Women With Metastatic Breast Cancer in the United States by Palliative Care Utilization
FDA Grants Fast Track Designation to SNB-101 in Small Cell Lung Cancer
Treatment with SNB-101 previously demonstrated tolerability among patients with solid tumors in a phase 1 trial.
61 High-Risk Screening Compliance in Women Diagnosed With Breast Cancer and a History of Thoracic Radiation Prior to Age 30
Six-Year Imatinib Maintenance Therapy Reduces Recurrence Risk in GIST
Investigators found that imatinib maintenance therapy for 6 years reduced the risk of recurrence in patients with gastrointestinal stromal tumors.
Fuzuloparib ± Apatinib Improves PFS in BRCA+ Metastatic Breast Cancer
Phase 2 data support the use of fuzuloparib with or without apatinib in HER2-negative metastatic breast cancer harboring BRCA1/2 germline mutations.
Pembrolizumab Combo Does Not Reach DFS End Point in Endometrial Cancer
Developers will work with investigators of the phase 3 KEYNOTE-B21 trial to share their findings with the scientific community.
62 The Impact of Genomic Assays on Breast Cancer Systemic Therapy Treatment Decisions in a Mostly Black Patient Population
Nivolumab Combo Significantly Boosts Survival in Urothelial Carcinoma
Findings from the CheckMate-901 study support the use of frontline nivolumab plus gemcitabine/cisplatin in advanced urothelial carcinoma.
63 Choice Architecture Bias in Genetic Counseling of Breast Cancer Patients
Setanaxib/Pembrolizumab Improves Survival in Head and Neck Cancer
Phase 2 data also highlight an improvement in disease control rate with setanaxib/pembrolizumab in squamous cell carcinoma of the head and neck.
64 Empowering Medical Students to Deliver Breast Health Education: A Community-Based Initiative
65 Racial Disparities in Treatment Patterns and Outcomes Among HER2-Low Metastatic Breast Cancer Patients Treated in US Community Oncology Practices
FDA Approves Noninvasive Stool RNA Test for Colorectal Cancer Screening
Data from the phase 3 CRC-PREVENT trial support the sensitivity of ColoSense in the detection of colorectal cancer.
Zenocutuzumab Earns FDA Priority Review in NRG1+ NSCLC, Pancreatic Cancer
Data from the phase 1/2 eNRGy trial support the biologics license application for zenocutuzumab in NRG1-positive NSCLC and PDAC.
ctDNA Shows Prognostic Value in Primary Breast Cancer
Findings suggest that patients with breast cancer and consistently negative circulating tumor DNA tests tend to have improved clinical outcomes.
Lasting Responses Observed With TAR-200 in BCG-Unresponsive NMIBC
All patients with a response to TAR-200 did not have progression to muscle-invasive bladder cancer or metastatic disease in the SunRISe-1 trial.
Nivolumab/Ipilimumab Receive Type II Validation by EMA in MSI-H/dMMR mCRC
CheckMate-8HW assessed the efficacy of first-line nivolumab plus ipilimumab in patients with MSI-H/dMMR metastatic colorectal cancer.